

AVMI Advocacy Strategy

Chidi Victor Nweneka, MBBS, PhD

Annual General Meeting of the African Vaccine
Manufacturing Initiative, Freetown, Sierra
Leone, September 24 & 25, 2018

Strategic Goal

The goal of the AVMI advocacy strategy is to grow sustainable and resilient development and manufacturing capabilities for human vaccines and biologicals in Africa

Strategic Objectives for 2018 – 2022

- To secure, by December 2019, the mandate of the AU to develop a Pan-African policy on vaccines and biologicals.
- To develop, by December 2020, in partnership with the African Union and African Regional Economic Communities, a five-year plan of action, for the establishment of a Vaccines and Biologicals Trust Fund for Africa.
- To secure, by December 2019, the endorsement of AVMI by the African Union and 50% of African Regional Economic Communities as the voice for vaccines and biologicals development and production in Africa.

Strategic Objectives for 2018 – 2022

- To expand AVMI's network of advocates for vaccine and biologicals manufacturing in 36 African countries by December 2019.
- To convene by 2019, in partnership with the AU, RECs and other key stakeholders, a high-level meeting on vaccines and biologicals manufacturing in Africa.

High Level Messages – main talking points of the advocacy strategy

- In line with the AU Agenda 2063, AVMI aims to grow sustainable and resilient human vaccine development and manufacturing capabilities that will accelerate socio-economic transformation in Africa
- Health security is a key component of national security and over-dependence on external vaccine suppliers poses a great risk to local health and national security of Africa. AVMI aims to break this cycle of dependency and thereby enhance local health and national security of African countries

High Level Messages – main talking points of the advocacy strategy

- AVMI aims to highlight the need of accelerating vaccine development and production in Africa.
- AVMI aims to integrate key stakeholders: governments, institutions of higher learning, and industry to form a progressive innovation ecosystem towards sustainable vaccines and biologicals development and production